[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 209 0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 64, "title": "CEO, President, Principal Accounting Officer, Principal Financial Officer & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 678300, "exercisedValue": 0, "unexercisedValue": 239308}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 77, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 52520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 58, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 673821, "exercisedValue": 0, "unexercisedValue": 161616}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  DiVecchia", "title": "Senior Vice President of Operations & Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.69, "open": 7.7034, "dayLow": 7.54, "dayHigh": 8.21, "regularMarketPreviousClose": 7.69, "regularMarketOpen": 7.7034, "regularMarketDayLow": 7.54, "regularMarketDayHigh": 8.21, "forwardPE": -2.7203138, "volume": 61666, "regularMarketVolume": 61666, "averageVolume": 40088, "averageVolume10days": 45640, "averageDailyVolume10Day": 45640, "marketCap": 98474648, "fiftyTwoWeekLow": 3.342, "fiftyTwoWeekHigh": 11.45, "fiftyDayAverage": 6.4685, "twoHundredDayAverage": 5.86288, "currency": "USD", "enterpriseValue": 88081040, "floatShares": 7766029, "sharesOutstanding": 12053200, "sharesShort": 145788, "sharesShortPriorMonth": 90799, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0121, "heldPercentInsiders": 0.28623, "heldPercentInstitutions": 0.09423, "shortRatio": 2.58, "shortPercentOfFloat": 0.0145000005, "impliedSharesOutstanding": 12053200, "bookValue": -1.761, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -46843000, "trailingEps": -3.44, "forwardEps": -2.57, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -2.17, "52WeekChange": 0.8309524, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.17, "targetHighPrice": 10.0, "targetLowPrice": 9.0, "targetMeanPrice": 9.5, "targetMedianPrice": 9.5, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 26016000, "totalCashPerShare": 2.414, "ebitda": -40586000, "totalDebt": 26050000, "quickRatio": 2.884, "currentRatio": 3.398, "returnOnAssets": -0.73697, "freeCashflow": -25206124, "operatingCashflow": -38219000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]